^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Calquence (acalabrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Calquence granted first regulatory approval in China for adults with previously treated mantle cell lymphoma
Published date:
03/23/2023
Excerpt:
AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This is the first approved indication for Calquence in China.
Source:
Excerpt:
CALQUENCE is a kinase inhibitor indicated for the treatment of adult patients with:...Mantle cell lymphoma (MCL) who have received at least one prior therapy.
Source:
Excerpt:
Mantle Cell Lymphoma: Preferred regimens...Acalabrutinib
TRIANGLE regimen: Alternating RCHOP + covalent BTKig/RDHA (rituximab, dexamethasone, cytarabine) + platinum (carboplatin, cisplatin, or oxaliplatin) (category 2A for ibrutinib; category 2B for acalabrutinib or zanubrutinib)
Secondary therapy:
R-CHOP
Source:
Title:
Acalabrutinib granted Breakthrough Therapy Designation by US FDA for the treatment of patients with mantle cell lymphoma
Published date:
08/01/2017
Excerpt:
AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
